Nephro protection property of double blockade versus single blocked of RAAS in delaying the progression of CKD
Date
2018-05
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Background: Dual renin angiotensin aldosterone system blockade using angiotensin receptor blockers in combination with angiotensin converting enzyme inhibitors is reported to improve proteinuria in non-diabetic patients.Methods: A prospective observational study was done on 810 non-diabetic chronic kidney disease patients during July 2012 to August 2014 to compare the nephro protection property of double blockade and single blocked of renin angiotensin aldosterone system in delaying the progression of chronic kidney disease.Results: At the end of 24 months urinary protein excretion rate of group I and group III were compared by using student t-test and p value (0.0001) was found significant. Similarly, on comparing group II and group III, p value (0.003) was again significant. Mean arterial blood pressure of group I and group III were statistically significant (<0.0496) while comparing group II and group III, p value (0.0419) was again significant.Conclusions: The study concludes that the use of double renin angiotensin aldosterone system blockade therapy is more effective than monotherapy at reducing albuminuria and proteinuiria, and in decreasing blood pressure at the same time not causing significant deterioration in glomerular filtration rate. Newer potassium lowering therapies can effectively and safely correct hyperkalemia and maintain normokalemia in patients receiving background treatment with renin angiotensin aldosterone system blockade. However, the use of new potassium binders for cardiovascular and renal risk reduction with combined renin angiotensin aldosterone system blockade therapy will require phase III trials.
Description
Keywords
CKD, Double blockade, Hyperkalemia, Non-diabetic, RAAS, Single blockade
Citation
Gupta Arvind, Narain Upma, Dabu Romar. Nephro protection property of double blockade versus single blocked of RAAS in delaying the progression of CKD. International Journal of Advances in Medicine. 2018 May; 5(3): 748-753